Abstract：【Objective】To explore the clinical efficacy of taxol combined with carboplatin on epithelial ovarian cancer. 【Methods】 A total of 80 patients with epithelial ovarian cancer admitted in our hospital from August 2015 to July 2017 were divided into two groups on the basis of random number table, with 40 cases in each group. The observation group was treated with the combination of taxol and carboplatin, while the control group received carboplatin only. Both groups were treated continuously for 2 courses, each lasting 2 weeks. The clinical efficacy, adverse reactions, changes of tumor markers [carbohydrate antigen (CA) 199, CA125, CA153, carcino-embryonic antigen (CEA)], and immune function indicators [CD3+T ratio, CD4+ ratio, CD8+ T ratio and CD4+/CD8+ value] as well as Karnofsky performance status (KPS) scores were compared between the two groups before and after treatment between the two groups. 【Results】The effective rate of the observation group was 82.50% (33/40),which was much higher than that of the control group 57.50% (23/40) (P<0.05). The incidence of adverse reactions of the observation group was 27.50% (11/40) and that of the control group was 22.50% (9/40). The difference in the incidence of adverse reactions between the two groups was not statistically different (P>0.05). After treatment both groups obtained significantly lower content of serum CA199, CA125, CA153, CEA and lower peripheral blood CD3+, CD4+, CD4+/CD8+ values (P<0.05). On the other hand, the proportion of CD8+ in peripheral blood was significantly increased (P<0.05). The serum levels of CA199, CA125, CA153, CEA and CD8+ in the observation group were significantly lower than those in the control group (P<0.05), and the peripheral blood CD3+, CD4+ ratio and CD4+/CD8+ values were significantly increased (P<0.05). The KPS score of the observation group 3 months after treatment was obviously higher than that before treatment (P<0.05), but there was no significant change before and after chemotherapy in the control group (P>0.05). 【Conclusion】 The combination of taxol and carboplatin in treating epithelial ovarian cancer can significantly lower the expression levels of serum tumor markers, regulate cellular immune function and improve patients' life quality, which is worthy of clinical application.
李程亮, 辛宏, 王敏娟, 石穎鹏. 紫杉醇辅助卡铂化疗方案治疗上皮性卵巢癌的疗效观察[J]. 医学临床研究, 2018, 35(11): 2097-2100.
LI Cheng-liang, XIN Hong, WANG Min-juan,et al. Clinical Study on Taxol Combined with Carboplatin in Treating Epithelial Ovarian Cancer. JOURNAL OF CLINICAL RESEARCH, 2018, 35(11): 2097-2100.
2018, Vol. 35 
